
St. Louis biomed firm was on the cusp of a breakthrough TB drug. Then its funding was cut.
ST. LOUIS — Fimbrion Therapeutics, a small but successful biomedical research business based in the city’s Cortex Innovation Center, was close to developing a key drug in the arsenal against tuberculosis, the world’s deadliest infectious disease. After …